Search
IN026 Developed by Lifetech Biosciences Obtains FDA Approval for Clinical Trials, Opening Up a New Pathway for Gout Treatment
22 hour ago /
Read about 0 minute
Author：小编
Lifetech Biosciences' IN026 is an investigational mRNA therapy targeting refractory gout, which has obtained FDA approval for clinical trials. This therapy achieves systemic degradation of uric acid in the body by delivering mRNA encoding urate oxidase (UOX) to the liver. In the Phase 1 clinical trial, the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IN026 in patients with unmet therapeutic needs will be evaluated.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
